Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development
businesswire.com
⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in